Arishel offers a broad range of services to the legal community, including scientific/medical/pharmaceutical evaluations, literature reviews, depositions, testimony, white papers, etc. Pharmaceutical and clinical pharmacology science areas include drug absorption, metabolism, excretion, toxicity, side-effects, dosage form considerations, drug interactions, overdoses, drugs of abuse, drug deaths, etc.
For the pharmaceutical industry, the following services are provided: protocol design & preparation; data analysis; report preparation
; IND sections; NDA sections; IDB preparation consulting & contracting; manuscript preparation; medical writing; in-house pharmacokinetic training; speaking engagements; troubleshooting; and legal expertise (advise, depositions, testimony, etc.)
Legal consulting services include, but are not limited to: rates of drug entry and exit from the body, drug activity & side-effects, drug interactions, pharmacology, drug-overdose, drug abuse, toxicology, data analysis, dosage form issues, drug labelling, standards of conduct, due diligence, malpractice, case analysis, patent issues, regulatory affairs, depositions, expert testimony, and laboratory tests and evaluations.
Expertise extends to virtually all areas of clinical practice -- psychiatric, cardiovascular, respiratory, gastrointestinal, hormonal, diabetes, endocrine and metabolism, oncology, analgesia, dermatology, nutrition, immunology, renal, neurology, infectious disease, and environmental/occupational hazards.
Dr. Boxenbaum is a full-time consultant who received a B.S. in Pharmacy (TempleUniversity) and a Ph.D. in Pharmaceutical Chemistry (School of Pharmacy, University of California at San Francisco in 1973. He taught at the Colleges of Pharmacy at Ohio State University and The University of Connecticut, but most of his career has been in the pharmaceutical industry (Hoffman-LaRoche, Marion Merrell Dow, Wyeth-Ayerst and Otsuka America Pharmaceutical). Harold has published over 75 research articles in diverse areas and serves on the editorial board of two scientific journals. He has been responsible for the design and analysis of innumerable clinical studies and the preparation of numerous submissions to the Food and Drug Administration.
